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http://www.humgenomics.com/content/7/1/11LETTER TO THE EDITOR Open AccessExome sequencing identifies nonsegregating
nonsense ATM and PALB2 variants in familial
pancreatic cancer
Robert C Grant1†, Wigdan Al-Sukhni1,2†, Ayelet E Borgida3, Spring Holter3, Zaheer S Kanji1, Treasa McPherson1,
Emily Whelan1, Stefano Serra4, Quang M Trinh5, Vanya Peltekova5, Lincoln D Stein5, John D McPherson5
and Steven Gallinger1,2,3,6*Abstract
We sequenced 11 germline exomes from five families with familial pancreatic cancer (FPC). One proband had a
germline nonsense variant in ATM with somatic loss of the variant allele. Another proband had a nonsense variant
in PALB2 with somatic loss of the variant allele. Both variants were absent in a relative with FPC. These findings
question the causal mechanisms of ATM and PALB2 in these families and highlight challenges in identifying the
causes of familial cancer syndromes using exome sequencing.
Keywords: Hereditary cancer, Pancreas cancer, Germline variants, Genetic counseling, CarcinogenesisLetter to the editor
ATM and PALB2 variants were recently associated
with familial pancreatic cancer (FPC) using exome
sequencing (ES). Roberts et al. identified germline
ataxia-telangiectasia (AT)-associated ATM variants in
two FPC kindreds through ES, then in an additional
4/166 FPC probands by Sanger sequencing [1]. Jones
et al. identified a frameshift variant in PALB2 with
somatic loss of heterozygosity in a patient with FPC
by ES. Inactivating PALB2 variants were found in an
additional 3/96 FPC kindreds [2].
We sequenced the germline exomes of 11 affected
individuals from five FPC families to search for predis-
posing mutations (Additional file 1: Table S1). Among
genes previously associated with FPC, we identified a
nonsense single nucleotide variant (SNV) in ATM and
a nonsense SNV in PALB2. These SNVs were absent in 47
FPC probands, 97 in-house controls, over 6,000 control
exomes, and dbSNP135 (Additional file 2).* Correspondence: Steven.Gallinger@uhn.ca
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reproduction in any medium, provided the orThe proband in family 1 carried the nonsense SNV in
ATM (c.C1931A; p.S644X), but her younger brother with
FPC did not (Figure 1A; Additional file 1: Table S2). Sanger
sequencing confirmed the exome calls and demonstrated
loss of the variant allele in DNA from a metastasis
(Figure 2A,B,C; Additional file 2). This SNV has not
been previously associated with AT.
The proband in family 2 carried the nonsense SNV in
PALB2 (c.C3256T; p.R1086X), but his younger cousin
with PC did not (Figures 1B and 2D,E,F; Additional file 1:
Table S2, columns d,f). Sanger sequencing of the primary
tumor demonstrated loss of the variant allele (Figure 2E).
A third cousin with PC was an obligate carrier of the SNV
(Figure 1B), as was this cousin’s sister and mother who
died from metastatic adenocarcinoma from unknown
primary sites (Figure 1B). This SNV was previously as-
sociated with FPC [2].
Inactivating variants in ATM or PALB2 are carried
by approximately 0.2% of the population [3], so find-
ing inactivating variants in two of the five kindreds
supports that these genes are associated with FPC.
Since the original ES studies [1,2], inactivating PALB2
mutations were found in small proportions of FPC
cohorts (for example, Tischkowitz et al. [4]), and somatic
ATM mutations were found in 8% of sporadic pancreatic
cancers [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Pedigrees of familial pancreatic cancer families, noting cancers, ages at diagnoses, and sources of diagnoses. (A) Family 1
(ATM c.C1931A; p.S644X). (B) Family 2 (PALB2 c.C3256T;p.R1086X). HX diagnosis from history, PA diagnosis from pathology reports, PSU primary site
unknown, SCC squamous cell carcinoma, BCC basal cell carcinoma.
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PALB2 predispose to FPC as ‘two hit’ tumor-suppressor
genes. Both probands had somatic loss of the variant
allele, not the wild-type allele. Moreover, both families
had a relative with FPC who did not carry the mutation,
with a younger age of onset than the affected carriers.
These non-carrier relatives may be phenocopies, which
is an important consideration for future ES studies.
Alternatively, other factors may cause the familial
clustering of pancreatic cancer in these kindreds.
ES is a promising technique to interrogate the genome
in search of causes of complex diseases. However, ES
generates thousands of candidates, and care is neededto avoid false associations. Alternative and complemen-
tary candidate gene discovery technologies such as
whole-genome sequencing, copy-number analysis, and
methylome analysis generate even more candidates. Since
the potential for spurious findings is higher with more
candidate variants, confirming associations with replication
and functional studies is especially important.
Functional studies are yet to elucidate the roles of
ATM and PALB2 in FPC and large prospective studies
assessing their associations with FPC do not exist. These
considerations, combined with our findings, currently
limit the interpretability and utility of clinical sequencing
of ATM and PALB2 in FPC.
Figure 2 Sequencing confirmed the exome calls and demonstrated loss of the variant alleles in matched tumors. (A) ATM c.C1931A in
the proband of family 1. (B) ATM c.C1931A in tumor of the proband of family 1, demonstrating loss of the variant allele. (C) Wild-type ATM c.
C1931A in the brother with PC of the proband of family 1. (D) PALB2 c.C3256T in the proband of family 2. (E) PALB2 c.C3256T in the tumor from
the proband of family 2, demonstrating loss of the variant allele. (F) Wild-type PALB2 c.C3256T in the cousin with PC of the proband of family 2.
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Additional file 1: Exome sequencing results and clinical and
pathological characteristics and outcomes for the individuals with
pancreatic cancer in the families. Table S1: Exome sequencing results.
Table S2: Clinical and pathological characteristics and outcomes for the
individuals with pancreatic cancer in the families with ATM c.C1931A and
PALB2 c.C3256T.
Additional file 2: Supplement to R. C. Grant et al. exome
sequencing identifies nonsegregating nonsense ATM and PALB2
variants in familial pancreatic cancer. The file describes the
supplementary methods used in the study such as patient recruitment,
sample preparation, exome sequence capture and Illumina sequencing,
Bioinformatics, and Sanger sequencing.Abbreviations
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